BOSTON-(BUSINESS WIRE)–Sonde Health, a health technology company committed to providing affordable health monitoring for everyone, has raised a $19.25 million Series B investment round led by Partners Investment, with participation from NEOM Company, KT Corporation and existing investors including co-founded PureTech Health and M Ventures. The company has raised a total of $35.25 million and will use the funding to drive its global commercial growth, deepen its respiratory and mental health monitoring technologies, and build capabilities for additional health conditions.
“Digital biomarkers are becoming a mainstay in healthcare. Today’s healthcare companies are realizing how voice biomarkers can engage people earlier in their health. The data and insights found in voice can support health monitoring and patient stratification so that problems become apparent long before a costly medical examination event occurs,” said David Liu, CEO of Sonde Health. “With voice and any listening device, affordable and effective health monitoring can be made available to most of the world.”
Sonde has the largest and most diverse voice data set with over 1.2 million voice samples from over 85,000 subjects across 4 continents. Sonde is the only voice biomarker company that offers AI/machine learning-based monitoring products for multiple health conditions and has developed the ability to embed its technology into device chipsets for passive and safe voice health monitoring.
Today, Sonde provides its enterprise voice biomarker technology to companies in several healthcare verticals, including telehealth, pharma, remote patient monitoring, and consumer/medical devices. Sonde licenses its platform to customers worldwide in two ways:
- Respiratory fitness: Sonde’s platform can detect and monitor respiratory diseases, such as asthma, from 6 seconds of voice. Patients engage in Sonde Respiratory Health Checks 2+ times per week.
- Mental fitness: Sonde’s platform can detect and monitor signs of depression and anxiety from a 30-second voice. Patients engage in Sonde’s mental fitness health checks 3+ times per week.
Development of a vocal biomarker
- MCI, COPD, general health: Sonde is developing new vocal biomarkers using its proprietary research-build-validate methodology with clinical partners.
Partners Vice President of Investments Joonsoo Kim will join Sonde’s board of directors. “Sonde is at the forefront of a vocal biomarker revolution that has the potential to change the way we discover, manage and understand our health. They have the deepest, high-quality data set combined with leading edge processing technology, giving them a significant competitive advantage,” he said. “We believe Sonde’s team and platform are poised to disrupt and add tremendous value to health monitoring around the world, and we’re excited to support the company’s mission to harness the power of voice for better health.”
Sonde’s fundraising follows a stream of new and expanded commercial partnerships to accelerate the development and adoption of voice biomarkers worldwide. KT Corporation, one of the world’s leading telecommunications companies, recently announced that it will work commercially with Sonde to grow its voice-based businesses, including its call centers and AI voice assistants for health monitoring. It will also deploy Sonde’s technology for digital therapy and telemedicine applications in Asia.
GN Group will integrate Sonde’s Mental Fitness vocal biomarker into its hearing products. The company is already working with Sonde to develop the MCI vocal biomarker. Qualcomm, which has already integrated Sonde’s vocal biomarkers into its mobile chipsets, has expanded the relationship to include its wearable chipsets. Koye Pharmaceuticals, which had already engaged Sonde to develop a vocal biomarker for COPD, has expanded the partnership to develop a new vocal biomarker for mental health for deployment in India.
For companies and organizations interested in partnering with Sonde, please visit sondehealth.com/contact.
About Sonde Health
Sonde is the leader in voice health monitoring. Sonde serves leading healthcare companies, suppliers, pharmaceutical manufacturers and OEMs through its Voice Biomarker Platform. Leveraging a best-in-class voice dataset of over 1.2 million samples from 85,000+ individuals across 4 continents, Sonde uses advanced audio signal processing, speech science and AI/machine learning to sense and analyze subtle voice changes due to changes in human physiology to provide key insights into health and well-being.
About Partners Investment
Partners Investment is a Seoul-based venture capital firm founded in 2000 investing in breakthrough healthcare and therapeutics technologies in Korea, North America, Europe and China. Partners Investment is founded on the belief that the quest for improved health will always be paramount and that investing in healthcare innovation will benefit patients with unmet medical needs.